The fight against COVID19
23.78k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| The fight against COVID19 | +0.96% | - | - | - |
| ^GSPC | -0.39% | +3.91% | +15.64% | +4791.76% |
14 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 156.62 | -1.93 | -1.22% | 4:00 pm GMT-5 | 6.57M | 6.83M | 377.03B |
| ABBV | AbbVie Inc. | 146.38 | +1.81 | +1.25% | 4:00 pm GMT-5 | 4.96M | 4.89M | 258.44B |
| PFE | Pfizer Inc. | 28.79 | -0.30 | -1.03% | 4:00 pm GMT-5 | 32.35M | 31.10M | 162.56B |
| SNY | Sanofi | 45.98 | -0.36 | -0.78% | 4:00 pm GMT-5 | 1.22M | 2.07M | 118.19B |
| GILD | Gilead Sciences, Inc. | 79.36 | +0.34 | +0.43% | 4:00 pm GMT-5 | 5.51M | 5.77M | 98.89B |
| REGN | Regeneron Pharmaceuticals, Inc. | 835.75 | +14.85 | +1.81% | 4:00 pm GMT-5 | 535.70k | 449.86k | 91.05B |
| GSK | GSK plc | 36.17 | -0.16 | -0.44% | 4:00 pm GMT-5 | 2.33M | 3.73M | 75.69B |
| TAK | Takeda Pharmaceutical Company Limited | 13.94 | -0.03 | -0.21% | 4:00 pm GMT-5 | 1.31M | 1.87M | 44.04B |
| MRNA | Moderna, Inc. | 80.6 | +2.32 | +2.96% | 4:00 pm GMT-5 | 4.37M | 4.10M | 30.73B |
| BNTX | BioNTech SE | 101.34 | +2.60 | +2.63% | 4:00 pm GMT-5 | 784.53k | 649.87k | 24.30B |
| VIR | Vir Biotechnology, Inc. | 9.46 | +0.17 | +1.83% | 4:00 pm GMT-5 | 766.28k | 1.46M | 1.27B |
| NVAX | Novavax, Inc. | 5.58 | -0.01 | -0.18% | 4:00 pm GMT-5 | 5.69M | 7.91M | 662.85M |
| INO | Inovio Pharmaceuticals, Inc. | 0.3795 | -0.02 | -3.97% | 4:00 pm GMT-5 | 2.21M | 3.50M | 103.60M |
ReutersAbbVie to buy drug developer Cerevel for $8.7 billion
It marks the second large deal for AbbVie in the past week, coming days after it agreed to buy cancer drug developer ImmunoGen for $10.1 billion in cash, highlighting its appetite to place big bets on promising new medicines. It is paying $45 per share in cash for Cerevel, which is developing drugs for Alzheimer's, Parkinson's, psychosis, epilepsy, and panic disorder. Its experimental drug emraclidine is in midstage trials as a treatment for schizophrenia that will yield data the company hopes can be used to seek regulatory approval.
Fox BusinessPfizer CEO slams presidents of elite colleges over ‘despicable’ antisemitism
Pfizer CEO Albert Bourla criticized the "despicable" testimony of three elite university presidents who were "hiding behind calls for 'context'" before deeming such rhetoric impermissible.
ZacksPfizer (PFE) Declines More Than Market: Some Information for Investors
In the most recent trading session, Pfizer (PFE) closed at $28.79, indicating a -1.03% shift from the previous trading day.
